SCHEMBL376966

SCHEMBL376966

CC(C)c1oc(-c2ccc(Cl)cc2Cl)nc1CCC(=O)c1ccccc1OC(=S)N(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 5/20 0.46
PPARA Q07869 5/20 0.46
PPARD Q03181 4/20 0.46
HSD17B10 Q99714 3/20 0.36
CNR1 P21554 1/20 0.34
FURIN P09958 1/20 0.34
MAPT P10636 3/20 0.33
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
NPSR1 Q6W5P4 2/20 0.33
LMNA P02545 1/20 0.33
TSHR P16473 3/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
TP53 P04637 1/20 0.33
ALDH1A1 P00352 4/20 0.32
HPGD P15428 3/20 0.32
GAA P10253 2/20 0.32
MAPK1 P28482 1/20 0.32
POLB P06746 1/20 0.32
MRGPRX4 Q96LA9 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2464485 0.86 PPARG (0.51) PPARGPPARAPPARDHSD17B10MAPT
SCHEMBL376965 0.85 PPARG (0.49) PPARGPPARAPPARDHSD17B10FURIN
SCHEMBL377173 0.84 PPARG (0.43) PPARGPPARAPPARDHSD17B10CNR1
SCHEMBL377172 0.77 PPARG (0.44) PPARGPPARAPPARDHSD17B10CNR1
SCHEMBL376949 0.76 PPARG (0.51) PPARGPPARAPPARDHSD17B10MAPT
SCHEMBL4755248 0.76 PPARG (0.50) PPARGPPARAPPARDHSD17B10MAPT
SCHEMBL4754218 0.75 PPARA (0.49) PPARGPPARAPPARDHSD17B10MAPT
SCHEMBL13296176 0.75 PPARG (0.52) PPARGPPARAPPARDHSD17B10MAPT
SCHEMBL4752344 0.75 PPARA (0.55) PPARGPPARAPPARDHSD17B10MAPT
SCHEMBL376648 0.74 PPARG (0.49) PPARGPPARAPPARDHSD17B10CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1310494-B1 PPAR (delta) ACTIVATORS NIPPON CHEMIPHAR CO (JP) 2012-01-25 EP disclosed
US-6787552-B2 HYPERGLYCEMIA, HYPERLIPIDEMIA, OBESITY, SYNDROME X; OXAZOLE OR THIAZOLE OR IMIDAZOLE DERIVATIVES NIPPON CHEMIPHAR CO., LTD. (JP) 2004-09-07 US disclosed
US-20040097739-A1 Ppar delta activators NIPPON CHEMIPHAR CO., LTD. (JP) 2004-05-20 US disclosed
EP-1310494-A1 PPAR (delta) ACTIVATORS NIPPON CHEMIPHAR CO., LTD. (JP) 2003-05-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097739-A1 Ppar delta activators PPARD, PPARG, PPARA PPARG 2/4885PPARA 3/4885PPARD 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.